Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS OTCMKTS:COTQF NASDAQ:HSTO OTCMKTS:MCUJF OTCMKTS:NRIFF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$5.58-4.8%$5.12$3.76▼$19.35$50.46M1.2556,173 shs199,073 shsCOTQFCritical Outcome Technologies$0.00$0.00▼$0.00N/AN/AN/AN/AHSTOHistogen$0.00+400.0%$0.00$0.05▼$0.55$5K1.1910,369 shs1,625 shsMCUJFMedicure$0.75$0.84$0.60▼$0.97$7.83M0.97165 shsN/ANRIFFNuvo Pharmaceuticals$0.00$0.30▼$0.87$8.52M1.577,337 shs3,000 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%-2.20%-0.56%-3.62%-58.46%COTQFCritical Outcome Technologies0.00%0.00%0.00%0.00%0.00%HSTOHistogen0.00%0.00%0.00%0.00%-95.83%MCUJFMedicure0.00%0.00%-6.77%-20.30%+25.36%NRIFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$5.58-4.8%$5.12$3.76▼$19.35$50.46M1.2556,173 shs199,073 shsCOTQFCritical Outcome Technologies$0.00$0.00▼$0.00N/AN/AN/AN/AHSTOHistogen$0.00+400.0%$0.00$0.05▼$0.55$5K1.1910,369 shs1,625 shsMCUJFMedicure$0.75$0.84$0.60▼$0.97$7.83M0.97165 shsN/ANRIFFNuvo Pharmaceuticals$0.00$0.30▼$0.87$8.52M1.577,337 shs3,000 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%-2.20%-0.56%-3.62%-58.46%COTQFCritical Outcome Technologies0.00%0.00%0.00%0.00%0.00%HSTOHistogen0.00%0.00%0.00%0.00%-95.83%MCUJFMedicure0.00%0.00%-6.77%-20.30%+25.36%NRIFFNuvo Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 2.40Hold$36.33551.14% UpsideCOTQFCritical Outcome Technologies 0.00N/AN/AN/AHSTOHistogen 0.00N/AN/AN/AMCUJFMedicure 0.00N/AN/AN/ANRIFFNuvo Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest COTQF, HSTO, MCUJF, ATOS, and NRIFF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026ATOSAtossa Genetics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$120.00 ➝ $24.003/26/2026ATOSAtossa Genetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$4.57 per shareN/ACOTQFCritical Outcome TechnologiesN/AN/AN/AN/AN/AN/AHSTOHistogen$19K0.28N/AN/A$3.13 per share0.00MCUJFMedicure$20.65M0.38N/AN/A$0.89 per share0.84NRIFFNuvo Pharmaceuticals$52.41M0.00N/A0.82$1.59 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$34.77M-$3.60N/AN/AN/AN/A-65.56%-57.74%5/12/2026 (Estimated)COTQFCritical Outcome TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/AHSTOHistogen-$10.62M-$2.81N/AN/AN/AN/AN/AN/AN/AMCUJFMedicure-$5.08M-$0.49N/AN/AN/A-24.61%-41.55%-25.94%5/19/2026 (Estimated)NRIFFNuvo Pharmaceuticals$2.53M$0.0418.69N/AN/A-2.81%8.02%1.11%N/ALatest COTQF, HSTO, MCUJF, ATOS, and NRIFF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2026N/AMCUJFMedicure-$0.0439N/AN/AN/A$3.63 millionN/A5/12/2026Q1 2026ATOSAtossa Genetics-$0.99N/AN/AN/AN/AN/A4/23/2026Q4 2025MCUJFMedicure-$0.0439-$0.29-$0.2462$999.00$3.62 million$6.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ACOTQFCritical Outcome TechnologiesN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/ANRIFFNuvo PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A5.535.53COTQFCritical Outcome TechnologiesN/AN/AN/AHSTOHistogenN/AN/AN/AMCUJFMedicure0.031.020.77NRIFFNuvo Pharmaceuticals5.272.672.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%COTQFCritical Outcome TechnologiesN/AHSTOHistogenN/AMCUJFMedicureN/ANRIFFNuvo PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipATOSAtossa Genetics9.80%COTQFCritical Outcome TechnologiesN/AHSTOHistogen3.30%MCUJFMedicure12.90%NRIFFNuvo PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics88.61 million7.77 millionOptionableCOTQFCritical Outcome TechnologiesN/AN/AN/ANot OptionableHSTOHistogen204.27 millionN/ANot OptionableMCUJFMedicureN/A10.44 million9.09 millionNot OptionableNRIFFNuvo Pharmaceuticals9911.40 millionN/ANot OptionableCOTQF, HSTO, MCUJF, ATOS, and NRIFF HeadlinesRecent News About These Companies4 Best Home Oxygen Concentrators Of 2024February 14, 2024 | forbes.comAbout NUVOApril 2, 2023 | nuvo.netNEPA Expresses Support for State-level Permitting for Carbon Capture and Sequestration ProjectsJanuary 15, 2023 | nuvo.netNMiravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South KoreaJuly 29, 2021 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026Defense Budget Expansion: 3 Mid-Cap Names in a Sweet Spot By Chris Markoch | April 20, 2026The Drone Disruptor: Kratos Stock Seeks a Higher Altitude By Jeffrey Neal Johnson | April 8, 2026COTQF, HSTO, MCUJF, ATOS, and NRIFF Company DescriptionsAtossa Genetics NASDAQ:ATOS$5.58 -0.28 (-4.78%) Closing price 04:00 PM EasternExtended Trading$5.88 +0.30 (+5.38%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Critical Outcome Technologies OTCMKTS:COTQFCotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.Histogen NASDAQ:HSTOHistogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.Medicure OTCMKTS:MCUJF$0.75 0.00 (0.00%) As of 05/1/2026Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Nuvo Pharmaceuticals OTCMKTS:NRIFFNuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
